Site Editor

Sandy Srinivas, MD


Sandy Srinivas, MD, on Treatment Alternatives for Metastatic Castration-Resistant Prostate Cancer During Radioligand Therapy Shortage

Posted: Wednesday, May 10, 2023

Sandy Srinivas, MD, of Stanford University School of Medicine, discusses alternative treatment options for patients who have metastatic castration-resistant prostate cancer and are awaiting the availability of the radioligand therapy lutetium Lu 177 vipivotide tetraxetan.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.